CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Placebo ComparatorWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2048 Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki 1.00
drug310 Bacille Calmette-Guérin (BCG) Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D000257 Adenoviridae Infections NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial

A novel betacoronavirus, SARS-CoV-2, is spreading rapidly throughout the world. A large epidemic in South Africa may overwhelm available hospital capacity and healthcare resources which would be worsened by absenteeism of healthcare workers and other frontline staff (HCW). Strategies to prevent morbidity and mortality of HCW are desperately needed to safeguard continuous patient care. Bacillus Calmette-Guérin (BCG) is a vaccine against tuberculosis (TB), with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, with reported morbidity and mortality reductions as high as 70%. We hypothesize that a BCG vaccination may reduce the morbidity and mortality of healthcare workers during the COVID-19 outbreak in South Africa.

NCT04379336 COVID-19 Sars-CoV2 Biological: Bacille Calmette-Guérin (BCG) Other: Placebo Comparator

Primary Outcomes

Description: To compare the incidence of HCWs hospitalized due to COVID-19 per arm.

Measure: Incidence of HCWs hospitalized due to COVID-19 per arm

Time: 52 weeks

Secondary Outcomes

Description: To determine the incidence of SARS-CoV-2 infection in HCW by molecular or serological testing (as available) at entry, 10, 26 and/or 52 weeks.

Measure: Incidence of SARS-CoV-2 infection per arm

Time: 52 weeks

Description: To compare the incidence of symptoms of upper respiratory tract infection per arm.

Measure: Incidence of upper respiratory tract infections per arm

Time: 52 weeks

Description: To compare the number of days of (unplanned) absenteeism because of documented SARS-CoV-2 infection, COVID-19 or any reason per arm.

Measure: Days of unplanned absenteeism due to COVID-19 or any reason per arm

Time: 52 weeks

Description: To compare the incidence of hospitalization of HCW for any reason per arm.

Measure: Incidence of hospitalization for any reason per arm

Time: 52 weeks

Description: To compare the incidence of intensive care admission of HCW due to COVID-19 or any reason per arm.

Measure: Incidence of intensive care unit admission per arm

Time: 52 weeks

Description: To compare the incidence of death of HCW due to COVID-19 or any reason per arm.

Measure: Incidence of death per arm

Time: 52 weeks

Description: To describe the prevalence of latent TB infection as determined by interferon gamma release assay (IGRA) at enrolment and at week 52.

Measure: Prevalence of latent TB infection

Time: 52 weeks

Description: To compare the incidence of active TB of HCW per arm.

Measure: Incidence of active TB per arm

Time: 52 weeks

Description: To compare the effect of latent TB infection on morbidity and mortality of HCW due to COVID-19 per arm. The risk of morbidity and mortality of latent TB infected individuals is not known, we will examine whether there is a higher risk of disease severity and poor outcomes in this group.

Measure: Compare the effect of latent TB on morbidity and mortality due to COVID-19 per arm

Time: 52 weeks

Description: To compare the incidence of grade 2 or higher adverse events and vaccination site reactions per arm.

Measure: Incidence of treatment related adverse events

Time: 52 weeks


No related HPO nodes (Using clinical trials)